BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 23617469)

  • 1. CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma.
    Mitrovic Z; Iqbal J; Fu K; Smith LM; Bast M; Greiner TC; Aoun P; Armitage JO; Vose JM; Weisenburger DD; Chan WC
    Br J Haematol; 2013 Jul; 162(1):87-92. PubMed ID: 23617469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
    Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
    Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
    Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype.
    Harris J; Ibrahim H; Amen F; Karadimitris A; Naresh KN; Macdonald DH
    Hematol Oncol; 2012 Mar; 30(1):8-12. PubMed ID: 21638304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
    Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
    Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
    Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
    J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL.
    Jabłońska J; Jesionek-Kupnicka D; Potemski P; Kowalik A; Sygut J; Kordek R
    Pol J Pathol; 2010; 61(3):124-32. PubMed ID: 21225494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis.
    Ma XB; Zheng Y; Yuan HP; Jiang J; Wang YP
    Hum Pathol; 2015 Apr; 46(4):593-9. PubMed ID: 25682152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression.
    Miyazaki K; Yamaguchi M; Suguro M; Choi W; Ji Y; Xiao L; Zhang W; Ogawa S; Katayama N; Shiku H; Kobayashi T
    Br J Haematol; 2008 Aug; 142(4):562-70. PubMed ID: 18537973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.
    Saad AA; Awed NM; Abdel-Hafeez ZM; Kamal GM; Elsallaly HM; Alloub AI
    Saudi Med J; 2010 Feb; 31(2):135-41. PubMed ID: 20174727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topo IIα gene alterations correlated with survival in patients with diffuse large B-cell lymphoma.
    Chen Z; Wang J; Zhang H; Liu D; Li Y; Xu Y; Tan D; Chen D; Zhao X; Wang G
    Eur J Clin Invest; 2012 Mar; 42(3):310-20. PubMed ID: 21880040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
    Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
    Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
    Wright G; Tan B; Rosenwald A; Hurt EH; Wiestner A; Staudt LM
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9991-6. PubMed ID: 12900505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.